- |||||||||| prednisolone / Generic mfg.
[VIRTUAL] Generalized bullous fixed drug eruption to Fluconazole without cross-reactivity to Itraconazole () - May 19, 2020 - Abstract #EAACI2020EAACI_2050;
Patient received prednisolone iv (0.7mg/kg) with tapering for 45 days, topical treatment and he presented with full recovery of the skin lesions after this time...Itraconazole can be used alternatively after in-vivo tests and drug provocation test. Statement of Consent for Presentation and Publication: The authors state they have obtained patients informed consent for presentation and publication of the present clinical case.
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
[VIRTUAL] Severe contact anaphylaxis to hair dye () - May 19, 2020 - Abstract #EAACI2020EAACI_1987;
Immediate anaphylaxis treatment was administered: epinephrine 0,5mg s/c, O2 therapy 7 l/min, perfusion NaCl 0,9% in two IV lines, prednisolone 50 mg, dexamethasone 8 mg, fexofenadine 180 mg... For first time we faced in emergency unit a severe anaphylaxis reaction from hair dye and the need to aware both patients and doctors to the importance of allergen avoidance in presence of early and light reaction evidence and properly diagnose to address potential risks and find possible alternatives to support patients life quality
- |||||||||| tacrolimus / Generic mfg., levocetirizine / Generic mfg.
[VIRTUAL] Atopic keratoconjuctivitis: Is there any role for sublingual immunotherapy? A case report () - May 19, 2020 - Abstract #EAACI2020EAACI_1860;
Symptoms were not controlled, despite the fact that she was on cyclosporin, prednisolone, olapatadine eye drops and artificial tears.The symptoms started at the age of 6 years, progressively deteriorated and wereworse from spring to summer, but between December and January the patient was asymptomatic...She is still using tacrolimus eye drops, the artificial tears and oral cetirizine...The next step is to consider grass immunotherapy, as symptoms are worse mainly during the summer. This case demonstrates that immunotherapy can play a role in difficult cases of atopic keratoconjuctivitis, when despite the fact that all available treatments have been tried, the patient is still suffering from severe symptoms.
- |||||||||| prednisolone / Generic mfg., Emerade (epinephrine) / Bausch Health, epinephrine / Generic mfg.
[VIRTUAL] The achenes role in the strawberry allergy () - May 19, 2020 - Abstract #EAACI2020EAACI_1696;
The Western-Blot showed a band between 20-25 kDa that can match with PR-5, a thaumatin analogue protein, far from LTP (9 kDa) or PR-10 (18 kDa). To the best of our knowledge, this is the first case published of allergy to strawberry achenes with tolerance of the fresh fruit.
- |||||||||| prednisolone / Generic mfg.
[VIRTUAL] Lip swelling after intense kissing () - May 19, 2020 - Abstract #EAACI2020EAACI_1532;
Total IgE, specific IgE screening for inhalant and food allergens, Tryptase-levels as well as C3c, C4, C1 INH-antigen and -activity levels taken on the ward were all within the normal range. Swelling receded within 3 days.
- |||||||||| prednisolone / Generic mfg.
[VIRTUAL] Cutaneous mastocytosis and selective IgM deficiency case report () - May 19, 2020 - Abstract #EAACI2020EAACI_1467;
The patient was treated with daily antihistamine and was given a preoperative protocol with sodium cromoglycate and prednisolone, and an anaphylaxis treatment plan...The rare association between mastocytocis and other immune-based diseases has been suggested in children. The follow-up of similar cases may be instrumental to the better understanding of the mechanisms underlying this association.
- |||||||||| prednisolone / Generic mfg., prednisone / Generic mfg.
Journal: Urinary excretion profile of prednisone and prednisolone after different administration routes. (Pubmed Central) - May 19, 2020
After systemic use, prednisone and prednisolone were both detectable for at least 24 h in concentrations ranging from 5 to 500 ng/mL and from 5 to 900 ng/mL respectively. Whereas, after topical administration, prednisone and prednisolone were detectable for at least 18 h in concentrations ranging from 5 to 140 ng/mL and from 5 to 50 ng/mL respectively.
- |||||||||| cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Journal: Transformation of CD5-positive nodal marginal zone lymphoma to diffuse large B-cell lymphoma (Pubmed Central) - May 19, 2020
Disease progression was revealed after 16 months, and she was initially treated with chemotherapy consisting of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP)...Subsequent therapy with rituximab and bendamustine also failed to induce remission...Cases of CD5-positive NMZL are rare; thus, it is difficult to study the clinical implications of CD5 expression in this disease. Here we describe the current understanding of CD5 expression in NMZL.
- |||||||||| Clinical Trial,Phase II, Journal: Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. (Pubmed Central) - May 19, 2020
These are the results of phase II study of bortezomib-melphalan-prednisolone (VMP) induction therapy followed by lenalidomide-dexamethasone (Rd) consolidation and lenalidomide maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)...Thus, VMP induction therapy followed by Rd consolidation and lenalidomide maintenance is considered a well-tolerated and effective regimen in transplant-ineligible NDMM. This trial is registered with UMIN-CTR with the identification number UMIN000009042.
- |||||||||| NN1213 / Novo Nordisk
Enrollment open, Trial completion date, Trial primary completion date: Acute Unilateral Vestibulopathy and Corticosteroid Treatment (clinicaltrials.gov) - May 18, 2020
P4, N=180, Recruiting,
This trial is registered with UMIN-CTR with the identification number UMIN000009042. Suspended --> Recruiting | Trial completion date: Dec 2020 --> Oct 2021 | Trial primary completion date: Dec 2020 --> Oct 2021
- |||||||||| prednisolone / Generic mfg.
Clinical, Clinical guideline, Journal: Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). (Pubmed Central) - May 17, 2020
The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed...Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy.
- |||||||||| cyclophosphamide intravenous / Generic mfg.
Clinical, Journal, IO Biomarker: Diagnostic delay in a case of T-cell neurolymphomatosis. (Pubmed Central) - May 17, 2020
However, symptoms recurred when prednisolone was weaned...This case highlights the diagnostic challenge in peripheral neurolymphomatosis related to patchy disease, variable sensitivity and specificity of investigative tools, and the influence of therapies on traditional cytological definitions of lymphoma. The clinical picture, exhaustive exclusion of alternative causes and the persistence of an abnormal T-cell clone ultimately lead to a diagnostic consensus between specialist neurology and haematology clinicians.
- |||||||||| doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] HEMATOLOGY EMERGENCY COMPLICATED BY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN INDOLENT LYMPHOMA () - May 16, 2020 - Abstract #EHA2020EHA_2315;
In reassessment after C4 R-CHOMP, there were no symptoms attributed to the hemato-oncological disease, functional gain in gait, biochemical response and a CT showing no hepatomegaly, diminished splenomegaly (134mm), left para-vertebral mass in D7 (15mmAP x 15mmCC) with less spinal cord compression. Conclusion This case becomes relevant due to early time of transformation (12 months) and the aggressive of clinical presentation which was complicated by an haematological emergency and HLH, showing the importance in early recognition and balance in HLH-specific and tumor-specific treatment, to prevent irreversible organ damage and subsequent death.
- |||||||||| doxorubicin hydrochloride / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA IN THE VERY ELDERLY (>80 YEARS OLD) () - May 16, 2020 - Abstract #EHA2020EHA_2108;
Treatment decisions are informed by patient fitness, co-morbidities, patient and family wishes, and impact patient outcome. Prospective trials are required in frail and elderly patients to better inform treatment decisions and optimal management strategies in DLBCL.
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
[VIRTUAL] ITP IN ADULTS: HOW THE EXPERIENCE OF A PERIPHERAL HOSPITAL CAN CONTRIBUTE TO THE STATE OF THE ART () - May 16, 2020 - Abstract #EHA2020EHA_1745;
Second-line treatment evaluation identified Splenectomy has the most frequent approach (n=9) in second-line treatment, followed by Eltrombopag (n=8)...Daily dose of prednisolone had long-term benefits...Conclusion In the last decade, changes in understanding the pathophysiology of this complex disorder have led to the publication of new guidelines for the diagnosis and management but ongoing treatment gaps endure and clinical practice is still crucial to achieve the better clinical outcome. With this data, the authors demonstrate that CS continues to be the gold-standard treatment in ITP adults, highlighting the role of high dose dexamethasone in the treatment of this complex disease.
- |||||||||| [VIRTUAL] THE EFFICACY OF OBINUTUZUMAB RETREATMENT IN OBINUTUZUMAB-INDUCED DIRECT CELL DEATH RESISTANT CD20-POSITIVE NON-HODGKIN LYMPHOMA MODEL () - May 16, 2020 - Abstract #EHA2020EHA_1358;
While the efficacy of OBI for r/r FL after rituximab was shown in some clinical trials, there is no evidence for the effectiveness of retreatment with OBI against r/r FL after OBI...The in vitro combination effects of OBI and each of the 5 agents [4-hydroperoxy-cyclophosphamide, doxorubicin (DXR), vincristine, prednisolone (PSL), and bendamustine] were assessed with a combination index (CI) based on the Bliss independence model: CI0 mean supra-additive, additive, and sub-additive effect, respectively...Conclusion OBI continued to be effective against cells resistant to OBI-induced direct cell death when combined with chemotherapeutic agents. Our results may warrant further investigation of OBI retreatment in patients previously treated with it.
- |||||||||| doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] TREATMENT PRACTICES AND PATIENT BURDEN IN MANTLE CELL LYMPHOMA PATIENTS IN THE REAL WORLD: AN OBSERVATIONAL, DATABASE RESEARCH IN JAPAN (CLIMBER-DBR) () - May 16, 2020 - Abstract #EHA2020EHA_1286;
Real-world evidence on MCL using secondary data sources has been reported in a US study using a commercial claims database, where bendamustine/rituximab (BR; 35.4%), rituximab/cyclophosphamide/doxorubicin/vincristine (R-CHOP; 24.9%), and rituximab monotherapy (12.9%) were the most common first-line treatments (Goyal et al...The most common regimens were BR (27.8%), R-CHOP (15.6%), and rituximab/pirarubicin/cyclophosphamide/vincristine/prednisolone (6.5%)...Treatment practices are consistent with trends observed in western countries. These results can serve as a broad benchmark to assess future treatments for MCL in Japan.
- |||||||||| tacrolimus / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER POST SOLID ORGAN TRANSPLANT – A HETEROGENOUS, AGGRESSIVE DISORDER: A MULTICENTRE REPORT () - May 16, 2020 - Abstract #EHA2020EHA_972;
Most patients received three immunosuppressants at diagnosis, including tacrolimus (24, 23.8%), mycophenolate (18, 17.8%), ciclosporine (15, 14.9%), azathioprine (12, 11.9%) and prednisolone (32, 31.7%)...Eight (20%) received single agent immunotherapy (Rituximab); 4 chemotherapy alone (10%); 18 (45%) received combined chemo-immunotherapy; and 2 (5%) received other treatment modality...Bone marrow involvement and increasing age were predictors of poor OS. Early mortality and poor response to frontline therapy are common, outlining the need for improved treatment strategies.
- |||||||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, doxorubicin hydrochloride / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] INOTUZUMAB OZOGAMICIN PLUS R-CVP IS A FEASIBLE AND EFFECTIVE REGIMEN FOR FRONTLINE TREATMENT OF DLBCL IN PATIENTS WHO ARE UNFIT FOR R-CHOP: RESULTS OF A RANDOMISED PHASE 2 UK NCRI TRIAL () - May 16, 2020 - Abstract #EHA2020EHA_417;
Fields et al (J Clin Onc 2014) demonstrated the efficacy of Gemcitabine (G) plus R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone) in pts at high risk of anthracycline toxicity...We did not demonstrate superiority for IO over G in this challenging pt group with high NRM. However, IO-R-CVP is an effective and deliverable regimen for DLBCL in high-risk, co-morbid pts, particularly those with high IPI, in whom fewer cycles of G-R-CVP were delivered.
- |||||||||| Decadron (dexamethasone) / Merck (MSD), hydrocortisone / Generic mfg.
[VIRTUAL] A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia () - May 15, 2020 - Abstract #ENDOI2020ENDO-I_101;
6 month, open label, study in 122 patients randomised either to treatment with MRHC (Chronocort®, Diurnal Ltd, Cardiff, UK) twice daily at ~ 0700h & ~2300h, or to remain on their standard GC regimen (hydrocortisone, prednisolone, prednisone, dexamethasone). Diurnal cortisol replacement with a MRHC improves the biochemical control of classic CAH with a twice-daily therapeutic regimen.
- |||||||||| doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Single centre experience of efficacy and tolerability of attenuated immunochemotherapy (R‐miniCHOP) in elderly patients with high‐grade non‐Hodgkin lymphoma () - May 14, 2020 - Abstract #BSH2020BSH_435;
Summary/Conclusion In our single centre experience at a small rural general hospital, attenuated immunochemotherapy proves an efficacious and generally well‐tolerated treatment regimen for elderly patients with high‐grade non‐Hodgkin lymphoma and can provide lasting remissions for a substantial number of patients in this age group. These data are broadly in line with a previous phase 2 study of R‐mini‐CHOP in patients aged over 80 years with DLBL and support the continued use of this regimen in elderly patients with high grade NHL receiving treatment in a variety of settings.
- |||||||||| doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Incidence of cardiotoxicity in anthracycline‐based chemotherapy in lymphoma patients: a single centre experience () - May 14, 2020 - Abstract #BSH2020BSH_429;
Until such guidelines are available in our centre, we propose to carry out a pre‐ and post‐treatment echocardiogram on all patients having anthracycline, a thorough review of cardiac risk factors, with prompt referral to cardiology when dysfunction is recognized and to continue to collect information on patients who develop anthracycline‐related cardiotoxicity. The CARDIAC Care study, which is currently investigating the use of cardiac markers in identifying high‐risk patients and the utilization of angiotensin receptor blockers and B‐blockers to prevent heart muscle injury related to chemotherapy, will be vital to future guidelines.
|
